The Nitrogen Of The Z Radical Is Directly Bonded To A Benzene Ring Which Is Directly Bonded To The C(=o) Group Patents (Class 514/535)
  • Patent number: 10251925
    Abstract: A pharmaceutical composition for dissolving and eliminating wart and excrescence consisting of protein is disclosed in the present invention. The pharmaceutical composition comprises (in 100 weight parts) 1.0-60.0 parts of sodium hydroxide and/or potassium hydroxide. The pharmaceutical composition further comprises 0.25-1.0 parts of tetracaine, bufalin, venenum bufonis and/or menthol having local anesthetic effect. The pharmaceutical composition can dissolve and eliminate wart and excrescence consisting of protein immediately and has significant effect and low side effect.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: April 9, 2019
    Inventors: Kuok Leong Tam, Io Cheng Tam, Io Man Tam
  • Patent number: 10064408
    Abstract: A concentrated treatment composition includes a bird repelling composition, a glycol, and a fragrance-containing/odor control composition. The concentrated treatment composition provides a stable product that is miscible with water. Methods for applying to the treatment compositions are also provided.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: September 4, 2018
    Assignee: AVIAN ENTERPRISES, LLC
    Inventor: Daniel R. Kramer
  • Patent number: 10047197
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: August 14, 2018
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin Sill, Adam Carie
  • Patent number: 9944752
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: April 17, 2018
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin Sill, Tomas Vojkovsky, Adam Carie, Joseph Edward Semple, Hooshmand Sheshbaradaran
  • Patent number: 9861647
    Abstract: Calcium glycerophosphate is found to be effective in treating and preventing a disease, disorder and/or condition of the respiratory system. The disease, disorder and/or condition is related to an obstructive or a restrictive condition of the respiratory airway.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: January 9, 2018
    Assignee: Prelief, Inc.
    Inventors: Alan E. Kligerman, Margaret T. Weis
  • Patent number: 9822243
    Abstract: The invention relates to freeze-dried compositions comprising a) at least one polymer based on polyacrylic acids and salts thereof, b) at least one natural polymer, c) optionally at least one further polymer which differs from a) and b) and d) optionally one or more active compounds and/or auxiliary substances. The invention furthermore relates to a process for the preparation of such freeze-dried compositions, the combination of such freeze-dried compositions in kit-of-parts arrangements together with aqueous solutions and the use of the freeze-dried compositions and of the kit-of-parts combinations for cosmetic and pharmaceutical use, in particular for use as a cosmetic mask or as a wound covering and for the preparation of pharmaceutical agents for treatment of dermal wounds, such as, in particular, chronic wounds, ulcus cruris or decubitus.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: November 21, 2017
    Assignee: DR. SUWELACK SKIN & HEALTH CARE AG
    Inventors: Ralf Malessa, Karin Wiesweg, Claudia Elsinghorst
  • Patent number: 9758474
    Abstract: The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: September 12, 2017
    Assignees: INCOZEN THERAPEUTICS PVT. LTD., RHIZEN PHARMACEUTICALS SA
    Inventors: Meyyappan Muthuppalaniappan, Prashant K. Bhavar, Srikant Viswanadha, Swaroop K. Vakkalanka, Gayatri S. Merikapudi
  • Patent number: 9688724
    Abstract: The present invention provides methods for limiting development of skin wounds, and also for treatment of one or more of erythemas, blisters, rashes, pruritis, contact dermatitis, psoriasis, eczema, acne, and athlete's foot.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 27, 2017
    Assignee: University of Southern California
    Inventors: Kathleen E. Rodgers, Gere S. diZerega
  • Patent number: 9592213
    Abstract: Disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof. Specifically disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof, which comprises tranilast as an active ingredient thereof.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: March 14, 2017
    Assignees: National University Corporation Kumamoto University, Keio University, Link Genomis, Inc.
    Inventors: Hidetaka Katabuchi, Ritsuo Honda, Hideyuki Saya, Yoshimi Arima, Shinichiro Niwa, Yasutaka Makino
  • Patent number: 9545408
    Abstract: Kits and methods for treating disordered or infected tissue caused by a virus in a mammal involve co-administering a systemic anti-virus drug and topically administered anti-infective composition. The systemic anti-virus drug is internally administered and disrupts or inhibits virus replication systemically within the mammal. Examples include nucleoside analogs, nucleoside analog precursors, and nucleotide analogs. The topically administered anti-infective composition includes at least one anti-infective agent, such as an organohalide (e.g., benzalkonium chloride), and is formulated to penetrate below the skin surface and allow the anti-infective agent to kill viruses at the infected tissue site. The topical anti-infective composition renders the systemic anti-virus drug more efficacious and reduces the time and/or number of dosages otherwise required for the systemic anti-virus drug to treat the disordered tissue.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: January 17, 2017
    Assignee: QUADEX PHARMACEUTICALS, INC.
    Inventor: B. Ron Johnson
  • Patent number: 9527807
    Abstract: Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: December 27, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shoji Fukumoto, Osamu Ujikawa, Shinji Morimoto, Yasutomi Asano, Satoshi Mikami, Norihito Tokunaga, Masakuni Kori, Toshihiro Imaeda, Koichiro Fukuda, Shinji Nakamura, Kouichi Iwanaga
  • Patent number: 9458095
    Abstract: The present invention includes bis- and tris-benzamide compounds that block AR signaling and have activity against prostate cancer. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: October 4, 2016
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jung-Mo Ahn, Ganesh Raj
  • Patent number: 9199927
    Abstract: [Problem] Provided is a compound which is useful as an agent for preventing and/or treating renal diseases. [Means for Solution] The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 1, 2015
    Assignee: Astellas Pharma Inc.
    Inventors: Jiro Fujiyasu, Kazuhiko Ohne, Susumu Yamaki, Tomoyoshi Imaizumi, Takeshi Hondo, Keisuke Matsuura, Tomohki Satou, Satoshi Sasamura
  • Patent number: 9102593
    Abstract: This invention relates to a novel chemical process for the synthesis of 2-ethyoxycarbonylamino-5-(4-fluorobenzylamino)-nitrobenzene and its use in the preparation of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene (retigabine/ezogabine) and its polymorphic forms thereof.
    Type: Grant
    Filed: January 16, 2012
    Date of Patent: August 11, 2015
    Assignee: Glaxo Group Limited
    Inventors: Russ N. Fitzgerald, Alan Millar, Jennifer Fell Toczko
  • Publication number: 20150133503
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating tuberculosis, comprising: (a) a pharmaceutically effective amount of a compound represented by the following chemical formula 1; and (b) a pharmaceutically acceptable carrier. Chemical formula 1 The compound contained as an active ingredient of the present invention inhibits the expression and activity of CO-DH in tubercle bacillus so as to effectively block the detoxification of carbon monoxide, which is an important survival factor of tubercle bacillus, and is safe for the human body since the compound targets CO-DH which does not exist in the human body. In addition, the compound creates a synergistic effect when combined with a conventional tuberculostatic drug, and thus can be more effective for treating tuberculosis.
    Type: Application
    Filed: February 13, 2013
    Publication date: May 14, 2015
    Inventors: Young Min Kim, Seung Jung Han, Tae Gwon Oh, Sae Woong Park, Sang Nae Cho, Mi Young Hahn, Jee Hee Suh, Kyu Yang Yi
  • Patent number: 9029417
    Abstract: The present invention, in one or more embodiments, comprises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecylcatechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising water soluble urushiol esters of general formula (I) Tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a composition containing at least one water soluble urushiol ester compound.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: May 12, 2015
    Assignee: The University of Mississippi
    Inventors: Mahmoud A. Elsohly, Waseem Gul, Mohammad Khalid Ashfaq, Susan P. Manly
  • Publication number: 20150126437
    Abstract: The disclosure provides compounds useful as insect repellents, compositions comprising such repellents, and methods of repelling an arthropod using such compounds and compositions. The disclosure further provides insect traps and method for identifying ligands and cognates for biological molecules.
    Type: Application
    Filed: October 17, 2012
    Publication date: May 7, 2015
    Applicant: The Regents of the University of California
    Inventors: Anandasankar Ray, Sean Michael Boyle
  • Publication number: 20150118285
    Abstract: The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.
    Type: Application
    Filed: September 10, 2014
    Publication date: April 30, 2015
    Inventors: Gilles H. Tapolsky, David W. Osborne
  • Publication number: 20150110851
    Abstract: A dissolving oral adhering patch with a dimple on at least one side to improve adhesion to hard convex surfaces in the mouth, including teeth, orthodontic braces and gums (keratinized gingiva). The patch may be designed to prevent or treat a sore in the mouth opposite a tooth or brace and may release a medication into the mouth, to treat a sore or to treat or prevent conditions elsewhere in the mouth or throat or stomach.
    Type: Application
    Filed: January 2, 2015
    Publication date: April 23, 2015
    Applicant: ORAHEALTH CORP.
    Inventor: Jeffrey T. Haley
  • Patent number: 9012477
    Abstract: A method for treating subjects experiencing neuropathic pain is provided. The method involves the application of a solid-forming local anesthetic formulation to a skin surface of the subject experiencing the neuropathic pain and then maintaining the formulation on the skin surface for a period of time sufficient to allow itself to transdermally deliver the local anesthetic to the subject thereby providing relief from the neuropathic pain within about 45 minutes.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: April 21, 2015
    Assignee: Nuvo Research Inc.
    Inventors: Jie Zhang, Robert Lippert
  • Patent number: 8987327
    Abstract: The present invention is directed to kits and methods for the treatment of a patient suffering from post-traumatic stress disorder (PTSD) and/or hot flashes by an administration of a mixture produced by a combination of a long acting local anesthetic combined with clonidine. The combination of the two pharmaceuticals produces a significant increase in duration and speed of onset of sympathetic blockade, increased intensity of the sympathetic blockage as well as the reduction of local anesthetic absorption locally. The combination significantly improves the efficacy, speed of onset and block intensity of a right sided cervical sympathetic ganglion injection (RCSGI) leading to increased length of resolution of PTSD and hot flashes as well as reducing the potential for complications related to absorption of the local anesthetic.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: March 24, 2015
    Inventor: Eugene Lipov
  • Publication number: 20150079035
    Abstract: The present invention provides, inter alia, a compound having the structure: (Formula (I). Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 19, 2015
    Inventors: Brent R. Stockwell, Scott J. Dixon, Rachid Skouta
  • Publication number: 20150072947
    Abstract: The present invention uses methylomic analysis and discovers DNA methylation biomarkers for prediction of ovarian cancer prognosis and detection of malignant ovarian cancer. In addition to being independent prognostic factors for patients with current treatment protocols, these DNA methylations are important biomarkers for individualized medicine for future chemotherapy (especially the demethylation agents or other epigenetic drugs).
    Type: Application
    Filed: August 30, 2012
    Publication date: March 12, 2015
    Applicant: National Defense Medical Center
    Inventors: Hung-Cheng Lai, Rui-Lan Huang
  • Patent number: 8969412
    Abstract: The present invention concerns a new use for a composition containing chloroprocaine HCl, and in particular its use for the manufacture of a drug for intrathecal narcosis. The present invention also concerns a new composition containing chloroprocaine HCl, being particularly suited to this new use, as well as a new method for manufacturing the composition.
    Type: Grant
    Filed: September 5, 2006
    Date of Patent: March 3, 2015
    Assignee: Sintetica S.A.
    Inventors: Augusto Mitidieri, Elisabetta Donati
  • Patent number: 8968710
    Abstract: A topical anesthetic is provided containing about 3 wt % to 10 wt % tetracaine in a vehicle suitable for administration to the skin or mucosa. The vehicle for transporting the tetracaine includes a water soluble mucoadhesive or a combination of mucoadhesives such as a high molecular weight poly(ethylene oxide) homopolymer and a cellulose polymer. The vehicle also includes propylene glycol. The tetracaine is ground into a powder and is suspended in a plasticized hydrocarbon gel which completes the vehicle.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: March 3, 2015
    Inventors: Alan J. Wickenhauser, Stephen E. Peipert
  • Patent number: 8952058
    Abstract: Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFR? kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: February 10, 2015
    Assignee: Ambit Biosciences Corporation
    Inventors: Michael J. Hadd, Michael D. Hocker, Mark W. Holladay, Gang Liu, Martin W. Rowbottom, Shimin Xu
  • Publication number: 20150025077
    Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.
    Type: Application
    Filed: February 27, 2013
    Publication date: January 22, 2015
    Applicant: COYOTE PHARMACEUTICALS, INC.
    Inventors: Hiroaki Serizawa, Ankush B. Argade, Akash Datwani, Natalie Spencer, Yonghua Pan, Florian Ermini
  • Publication number: 20150018371
    Abstract: Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions containing the positive allosteric modulators and methods of treating obesity or an obesity-related disorder such as type 2 diabetes, comprising administering an effective amount of the positive allosteric modulator.
    Type: Application
    Filed: March 6, 2013
    Publication date: January 15, 2015
    Inventors: Roger D. Cone, Julien A. Sebag, Jacques Pantel, Savannah Y. Williams, David C. Weaver, Gary A. Sulikowski, Craig W. Lindsley, Padma S. Portonova, Chao Zhang
  • Patent number: 8927606
    Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: January 6, 2015
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shirou Sawa, Shuhei Fujita
  • Publication number: 20150004206
    Abstract: The invention relates to a process for preparing PCL-comprising microparticles, to microparticles obtainable by said process, to gel hence obtained and to several uses of the gel such as for the preparation of a medicament for treating a skin abnormality or disfigurement, and/or for controlling bladder function and/or controlling gastric reflux and/or for treating erectile dysfunction and/or for treating vocal cords. The gel may also be used for cosmetic applications.
    Type: Application
    Filed: July 1, 2014
    Publication date: January 1, 2015
    Inventors: Henderikus Supèr, Paul Willem Mijnen, Pieter Gerard Zijlstra, Dirk Wybe Grijpma
  • Publication number: 20150004216
    Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Inventor: Robert Steven Davidson
  • Patent number: 8901169
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: December 2, 2014
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Erik Fenster, Melissa Fleury, Adam D. Hughes
  • Publication number: 20140336254
    Abstract: A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and reacts chemoselectively with one or two of four Lys-15 ?-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated with amyloidogenesis.
    Type: Application
    Filed: April 14, 2014
    Publication date: November 13, 2014
    Inventors: Jeffery W. Kelly, Sungwook Choi
  • Publication number: 20140323568
    Abstract: The present invention includes bis- and tris-benzamide compounds that block AR signaling and have activity against prostate cancer. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided.
    Type: Application
    Filed: April 23, 2014
    Publication date: October 30, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jung-Mo AHN, Ganesh RAJ
  • Patent number: 8871813
    Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: October 28, 2014
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shirou Sawa, Shuhei Fujita
  • Publication number: 20140315955
    Abstract: The present inventions are directed to novel aqueous compositions comprising a copolymer having water-soluble units and pendant catechols, said composition adapted for use on mammalian tissue and having a lower critical solubility temperature (LCST) of less than a physiological temperature, and their use, for example, in removing foreign particles from tissue surfaces, including ocular surfaces.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Inventors: HOYONG CHUNG, ROBERT H. GRUBBS, DANIEL M. SCHWARTZ
  • Publication number: 20140303248
    Abstract: A N-benzylaniline derivative and uses thereof. The derivative is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound protects against cerebral ischemia/reperfusion injury and has analgesic action for chronic pathologic pain, and may be used to treat cerebral apoplexy, neuropathic pain, and inflammatory pain. Moreover, because of the unique mechanism of action of the compound, the compound can be used to treat epilepsy, affective disorder, and neurodegenerative diseases.
    Type: Application
    Filed: October 24, 2012
    Publication date: October 9, 2014
    Inventors: Dongya Zhu, Fei Li, Chunxia Luo
  • Publication number: 20140301954
    Abstract: The present invention provides methods of administering an active agent to a specifically identified area of mucous membrane of a human being, as well as a body dissolving film formed therefore.
    Type: Application
    Filed: June 18, 2014
    Publication date: October 9, 2014
    Inventor: Andrew L. Skigen
  • Publication number: 20140288174
    Abstract: This disclosure relates to inhibitors of the Wni pathway, and compositions comprising the same, as well as to their use in the treatment of disorders characterized by the activation of Writ pathway signaling (e.g., cancer), as well as to the modulation of cellular events mediated by VVnt pathway signaling.
    Type: Application
    Filed: October 25, 2012
    Publication date: September 25, 2014
    Inventors: Sam W. Lee, Anna I. Mandinova
  • Publication number: 20140286876
    Abstract: The present invention, as described above and as further defined by the claims, provides methods of administering an active agent via adhesion of a film to a mucous membrane in the oral cavity of a mammal, as well as and ODF formed therefore. An active agent may be ingested as the ODF dissolves resulting in systemic treatment of the mammal. In additional embodiments, an ODF may provide topical administration of an active agent.
    Type: Application
    Filed: March 28, 2014
    Publication date: September 25, 2014
    Inventor: Andrew L. Skigen
  • Publication number: 20140275248
    Abstract: Methods for treating molluscum contagiosum warts include identifying a human with one or more molluscum contagiosum warts and applying an anti-infective composition to the one or more warts. The anti-infective composition comprises at least one anti-infective agent in a liquid carrier, such as an organohalide. The liquid carrier includes a tissue penetrating component for rapid penetration of the anti-infective agent into the one or more molluscum contagiosum warts. Application of the anti-infective composition to molluscum contagiosum warts causes the warts to turn black and/or fall off the skin in less than about 5 days.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventor: B. Ron Johnson
  • Patent number: 8821876
    Abstract: Methods of identifying infectious disease infection prior to presentation of symptoms, assays for identifying genomic markers of infectious disease, and methods for diagnosing the underlying etiology of infectious disease.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: September 2, 2014
    Assignee: Duke University
    Inventors: Geoffrey S. Ginsburg, Joseph Lucas, Christopher W. Woods, Lawrence Carin, Aimee K. Zaas, Alfred Hero
  • Publication number: 20140243379
    Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 28, 2014
    Applicant: MYLAN TECHNOLOGIES, INC.
    Inventors: Sharad K. Govil, Ludwig J. Weimann
  • Publication number: 20140234395
    Abstract: Transdermal or topical plasters containing active ingredient are provided that include a non-occlusive back layer, a matrix formed from of one or more polymer layers having at least one pharmaceutical active ingredient in one or more of the layers, in which the structure-forming base polymers of the layer(s) are non-occlusive or only slightly occlusive and a second polymer that has a low water-vapor permeability and that is immiscible or only very slightly miscible with the base polymer is dispersed in at least one of the polymer layers.
    Type: Application
    Filed: September 25, 2012
    Publication date: August 21, 2014
    Applicant: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Walter Müller, Patrick Mohr
  • Publication number: 20140234396
    Abstract: The present invention provides to patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation. In an external patch in which an adhesive layer containing an adhesive base and a drug are laminated with a backing, the external patch wherein the adhesive base contains 5-50% by weight of synthetic rubber polymer, 10-60% by weight of adhesive resin and 25-60% by weight of liquid paraffin, and the drug is etofenamate. According to the present invention, there is obtainable the patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation.
    Type: Application
    Filed: April 29, 2014
    Publication date: August 21, 2014
    Applicants: TEIKOKU SEIYAKU CO., LTD., DROSSAPHARM AG
    Inventors: Tomohiro ISHIMA, Hiroyuki YAMASAKI, Masahiro YAMAJI
  • Publication number: 20140213552
    Abstract: The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.
    Type: Application
    Filed: March 20, 2014
    Publication date: July 31, 2014
    Applicant: Endo Pharmaceuticals Inc.
    Inventors: Scott Kevin Thompson, Roger Astbury Smith, Sandeep Gupta, Tony Priestley, Nicholas James Laping, Ashis K. Saha, Sonali Rudra
  • Publication number: 20140187510
    Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.
    Type: Application
    Filed: July 11, 2013
    Publication date: July 3, 2014
    Applicants: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR CENTER FOR COMMERCIALIZATION
    Inventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
  • Patent number: 8759391
    Abstract: A topical anesthetic for rapid local anesthesia is provided. The topical anesthetic includes an anesthetic, volatile and non-volatile solvents, and a thickener. In addition, a method is taught for applying the topical anesthetic to the face of a patient without occlusion. The anesthetic is applied topically to an area for injection such that the dermatological procedure (cosmetic injections) can be performed in fifteen minutes.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: June 24, 2014
    Assignee: Juventio, LLC
    Inventors: David M. Cohen, Eugene R Cooper
  • Patent number: 8754124
    Abstract: The present invention includes bis- and tris-benzamide compounds that block AR signaling and have activity against prostate cancer. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: June 17, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jung-Mo Ahn, Ganesh Raj
  • Patent number: 8754131
    Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: June 17, 2014
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shirou Sawa, Shuhei Fujita